Man Group
JANX icon

Man Group’s Janux Therapeutics JANX Stock Holding History

Man Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Sell
248,801
-94,185
-27% -$1.36M 0.01% 1264
2026
Q1 		$4.77M Buy
342,986
+278,474
+432% +$3.82M 0.01% 1193
2025
Q4 		$890K Buy
+64,512
New +$1.52M ﹤0.01% 1711

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Man Group's JANX Position: Q2 2026 in Review

Man Group reduced its Janux Therapeutics (JANX) stake by 27% in Q2 2026, selling an estimated $1.36M and leaving 248,801 shares worth $3.82M. The position accounts for 0.01% of the portfolio, ranked #1264.

Man Group first reported a position in JANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.77M in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Man Group held 248,801 shares of Janux Therapeutics worth $3.82M as of Q2 2026.
  • Man Group sold 94,185 Janux Therapeutics shares in Q2 2026, an estimated $1.36M.
  • Janux Therapeutics made up 0.01% of Man Group's portfolio in Q2 2026, its #1264 holding.
  • Man Group first reported a position in Janux Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Man Group's Janux Therapeutics position peaked at $4.77M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.